Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clever Leaves Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.27.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clever Leaves Holdingscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Clever Leaves Holdings's Cash-to-Debt or its related term are showing as below:
CLVR's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.98 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Clever Leaves Holdings Cash-to-Debt Related Terms
Clever Leaves Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clever Leaves Holdings Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Clever Leaves Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clever Leaves Holdings (CLVR) has a Cash-to-Debt of 3.27 as of Dec. 2023.
Is Clever Leaves Holdings' Cash-to-Debt too high?
Clever Leaves Holdings' current Cash-to-Debt is 3.27. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Clever Leaves Holdings' value of 3.27 is 233.7% above this industry median. Overall, Clever Leaves Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Clever Leaves Holdings' Cash-to-Debt compare to CNNC and CLSH?
Clever Leaves Holdings' Cash-to-Debt of 3.27 can be compared against companies in the Drug Manufacturers industry. The industry median Cash-to-Debt is 0.98. Clever Leaves Holdings' value of 3.27 is 233.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clever Leaves Holdings's current Cash-to-Debt of 3.27 is 233.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clever Leaves Holdings's current Cash-to-Debt is 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clever Leaves Holdings stock overvalued right now?
Clever Leaves Holdings (CLVR) has a current Cash-to-Debt of 3.27. The current Cash-to-Debt is 3.27 and 233.7% above the Drug Manufacturers industry median of 0.98. Clever Leaves Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Clever Leaves Holdings (CLVR), the current Cash-to-Debt is 3.27 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments namely, the Cannabinoid segment which is comprised of the company's cultivation, extraction, and commercialization of cannabinoid products; and the Non-Cannabinoid operating segment which generates maximum revenue and is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
12GF Score
Get the complete analysis for CLVR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVR has been successfully added to your 
